Proteogenomics provides clues about acute drug response in acute myeloid leukemia
Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.
Stay updated with breaking news from Karl Weitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.
Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.
Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.
Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed, thanks to a study o